Beranda › Kanker Payudara Triple-Negatif › Texas › Dallas
Uji klinis Kanker Payudara Triple-Negatif di Dallas, TX
18 studi untuk Kanker Payudara Triple-Negatif mencari peserta di lokasi sekitar Dallas (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Menerima pesertaFase 1/2
- UT Southwest Simmons Cancer Center, Dallas
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
Menerima pesertaFase 1
- UT Southwestern, Dallas
Study of AVZO-021 in Patients With Advanced Solid Tumors
Menerima pesertaFase 1/2
- Avenzo Therapeutics Recruiting Site, Dallas
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
Menerima pesertaFase 3
- Texas Oncology - DFW ( Site 8007), Dallas
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
Menerima pesertaFase 3
- Texas Oncology - DFW ( Site 8000), Dallas
- Parkland Health & Hospital System ( Site 0096), Dallas
- University of Texas Southwestern Medical Center ( Site 0032), Dallas
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Menerima pesertaFase 3
- Texas Oncology - DFW ( Site 8009), Dallas
- UT Southwestern ( Site 0092), Dallas
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
Menerima pesertaFase 1
- University of Texas Southwestern Medical Center, Dallas
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
Menerima pesertaFase 1
- Normunity Investigational Site, Dallas
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Menerima pesertaFase 1/2
- Mary Crowley Cancer Research, Dallas
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Menerima pesertaFase 1
- University of Texas Southwestern Medical Center - Simmons Cancer Center, Dallas
- UT Southwestern Medical Center - Redbird, Dallas
- Univ. of TX Southwestern Medical Center - Zale Lipshy University Hospital, Dallas
- dan 2 lainnya
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
Menerima pesertaFase 1/2
- Texas Oncology, P.A., Dallas
Study of XB010 in Subjects With Solid Tumors
Menerima pesertaFase 1
- Baylor University Medical Center, Dallas
BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
Menerima pesertaFase 1
- Baylor University Medical Center, Dallas
A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer
Menerima pesertaFase 1/2
- Texas Oncology - DFW, Dallas
JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
Menerima pesertaFase 1/2
- Mary Crowley Cancer Research, Dallas
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
Menerima pesertaFase 1
- Dren Investigational Site, Dallas
Neratinib in Combination With Ruxolitinib in Patients With mTNBC
Menerima pesertaFase awal 1
- Baylor University Medical Center, Baylor Charles A Sammons Cancer Center, Dallas
A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors
Menerima pesertaFase 1
- NEXT Oncology, Dallas, Dallas
Uji klinis Kanker Payudara Triple-Negatif di kota lain
- Houston, TX42 studi
- New York City, NY31 studi
- Nashville, TN28 studi
- Los Angeles, CA27 studi
- Boston, MA26 studi
- San Antonio, TX23 studi
- St. Louis, MO21 studi
- Arlington, VA20 studi
- Atlanta, GA20 studi
- Chicago, IL16 studi
- Columbus, OH16 studi
- Grand Rapids, MI15 studi
Studi lain di Dallas
- Kanker Payudara55 studi
- Kanker Paru Non-Sel Kecil52 studi
- Kanker Metastatik42 studi
- Gagal Jantung42 studi
- Kanker (semua jenis)37 studi
- Kanker Prostat36 studi
- Kanker Kolorektal33 studi
- Obesitas30 studi
- Kanker Ovarium28 studi
- Kanker Paru27 studi
- Kanker Kandung Kemih27 studi
- Kanker Endometrium24 studi
Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.